Navigation Links
US Oncology Welcomes New Director of Federal Government Relations
Date:4/24/2008

Geoff Werth to Lead Expansion of Organization's DC-Based Legislative Initiatives

WASHINGTON, April 24 /PRNewswire-USNewswire/ -- The US Oncology Government Relations and Public Policy department announced today the appointment of Geoff Werth to its newly created Director of Federal Government Relations position. Based in the organization's Washington, D.C. office, Werth will focus on extending US Oncology's reach on Capitol Hill in order to advance public policies designed to improve the delivery of high-quality community-based cancer treatment and cancer research nationwide.

"We are pleased to have Geoff join our government relations team at US Oncology, and we look forward to working with him to expand upon our current programs that are advancing quality cancer care across America," said Dan Cohen, Senior Vice President of Government Relations and Public Policy, US Oncology. "With his unique background as a passionate healthcare advocate, legislative staffer and trained medical technician, we are fortunate to have him on board."

With more than 10 years of experience in the legislative arena, including most recently spending nearly four years as a lobbyist in the Washington, D.C. office of the American College of Surgeons (ACS), Werth is well positioned to bring new leadership to US Oncology's public policy initiatives. Prior to his time with ACS, Werth worked on Capitol Hill for Congressman Bart Stupak (D-MI), Chairman of the House Energy and Commerce Committee's Oversight and Investigations Subcommittee; and in the leadership office of Minority Leader Dick Gephardt (D-MO). He also has experience in the healthcare field and is trained as a medical technologist.

"I look forward to applying my experience in federal legislative and medical affairs toward new opportunities with US Oncology," said Werth. "Advancing cancer care is one of the most pressing challenges our nation faces today, and I am proud to be working with an o
'/>"/>

SOURCE US Oncology
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Genomic Health Announces Multiple Studies on Oncotype DX(TM) Presented at 2007 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium
2. ESMO, Oxford Journals and the Japanese Society of Medical Oncology announce collaboration
3. SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference
4. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
5. US Oncology to Report 2007 Third Quarter Earnings Results
6. VioQuest to Present Data on Oncology Compounds VQD-002 and Lenocta(TM) at AACR-NCI-EORTC International Meeting
7. Genomic Health Reports Inclusion of Oncotype DX(TM) in American Society of Clinical Oncology Guidelines
8. Varian Medical Systems Ranks First in Overall Service Performance in 2007 Survey of U.S. Radiation Oncology Professionals
9. Accuray Announces Four New Products at Nations Leading Radiation Oncology Meeting
10. Debiopharm and NanoCarrier Sign License and Supply Agreement for Dach-Platin Polymeric Micelle in Oncology
11. National Autism Association and Deirdre Imus Environmental Center for Pediatric Oncology Announce National Greening Your School Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)..., COLLEGE PARK, MD. - A long history of terrori...s in Mumbai. The Global Terrorism Database (GTD), ...tional Consortium for the Study of Terrorism and R...00 terrorist attacks in India since 1970. Fataliti...eely available online. , The GTD is the most com...
(Date:12/2/2008)...ASHINGTON, Dec. 2 EIN N...te providing in-depth news on lung cancer. , ,...atients are finding out that information is one of..., Responding to the growing demand for accurate ...creening procedures and drugs to treat it, EIN New...
(Date:12/2/2008)..., , ROCKVILLE, Md., Dec. 2 /PRNewswire-USNe...ed sleep periods and increased supervision of work...ining environment, according to a new Institute of...are Research and Quality. , , The report i...ee that reviewed the relationship between resident...
(Date:12/2/2008)...OCHESTER, N.Y., Dec. 2 V...provider of quantitative imaging for clinical,tri...ceeds $27 million,compared to $14.7 million at th...se. The company calculates backlog as the amount r... contracts. The duration of the studies,included ...
Breaking Medicine News(10 mins):Health News:India terrorism by the numbers 2Health News:EIN News Introduces 'Lung Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 2Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 3Health News:New Report Recommends Strategies to Reduce Medical Resident Fatigue-Related Errors and Improve Training 4Health News:VirtualScopics Backlog Rises to a Record $27 Million 2Health News:VirtualScopics Backlog Rises to a Record $27 Million 3
...mount Americans spent on arthritis medications mor...ast-rising number of people// with the disease, in...h month and the inflation-adjusted cost per prescr...by a UCSF researcher. Results from a six-year stu...
...ebate on abortion is polarizing the US. Striking a...Spitzer has said that he would introduce// a bill ...week a conservative-dominated Supreme Court upheld...Ban Act, signed by President Bush in 2003. The ban...
...esponsibility and resources for public health and ...al councils rather than with the NHS, argues an ex...f Durham University says that partnerships between...HS would then become a true meeting of the two sid...
...tists at the Lundberg Laboratory for Cancer Resear...cademy in Sweden have discovered a //new hereditar...red that women possessing a certain hereditary def...k , almost twenty times, of contracting breast can...
Other Medicine News:Health News:Treatment Cost for Arthritis on the Rise: Study 2Health News:New York Governor to Introduce Bill to Strengthen Abortion Rights 2Health News:Local Councils Should Be Responsible for Tackling Health Inequalities 2Health News:Gene Behind Breast Cancer Found 2
(Date:12/1/2008)... SINGAPORE, Dec. 1 S*BIO Pte Ltd ...ical trial of SB1518, a potent and orally-active J...alia for patients with chronic idiopathic myelofib... evaluate the safety and tolerability of SB1518 in... 50 patients. The Phase 1 part of the study will ...
(Date:12/1/2008)... Baby Girl with Hypophosphatasia Treated With ENB...re in Winnipeg , , MONTREAL, Dec. 1 /PRNews...ch company focused on developing novel therapeutic... the first infant patient in its clinical program ...ating Enzyme Replacement Therapy (ERT) with ENB-00...
(Date:12/1/2008)... , Abstinence is still the best policy , ...ire/ -- A new study from Mayo Clinic finds the use...ating alcoholic hepatitis, an acute inflammation o...ohol. The results of the study are published in th...w.gastrojournal.org/ ). , , VIDEO ALERT: A...
(Date:12/1/2008)... KVISTGARD, Denmark, December 1 /PRNewswire-F...ued in 2007 with the intent to procure an MVA-base...s and Government Services,Canada, on behalf of th...rded,a contract to Bavarian Nordic for the delive...es intend to use IMVAMUNE(R) as part of the,count...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 1BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 3Anesiva Announces May 22 2008 Presentation at Citi Investment Research Global HealthCare Conference 19576 1New Gene Methylation Test for Prostate Cancer Available 2096 1Jazz Pharmaceuticals to Present at Investor Conferences 19573 1
...(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, I...ed today that the,first results from testing of a ...T-VACC™, have been published in the journal,... Infection and,Immunity, v. 75, p. 3043 ). These r...immunity elicited by a multivalent vaccine,that is...
... Update to Timeline for Second Pivotal Phase 3 Tri...Call/ -- Advanced Life,Sciences Holdings, Inc. , t...ficacy data from Trial CL-06, the first of two,piv...e safety and,effectiveness of cethromycin, a novel...nity acquired pneumonia (CAP). The Company,also pr...
Other Medicine Technology:DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),
Steroid-eluting, screw-in pacing lead
Tendril SDX is one of the world's thinnest, extendable/retractable pacing leads. Implantable with a 7 F introducer, the lead's reduced body diameter is designed to lower the incidence of venous obstr
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase.
Medicine Products: